New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
09:02 EDTPRANPrana completes PBT2 dosing in IMAGINE Alzheimer's Disease trial
Prana Biotechnology announced the completion of the treatment phase of its IMAGINE Alzheimer's Disease clinical trial. There were 42 patients with prodromal or mild AD enrolled in the Phase II double-blind placebo-controlled clinical trial of Prana's novel drug, PBT2. A total of 40 patients completed the planned 12 months of treatment with PBT2, or placebo, bringing the treatment phase of the trial to a close. Only two patients withdrew during the trial representing a trial retention rate of 95%. An independent Data Safety Advisory Board met five times during the course of the trial and on no occasion made any recommendations to vary the original trial protocol. The data compilation and statistical analysis will commence shortly after the last few patients complete their follow up visit, with results expected in March 2014.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PRAN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use